use of Darovasertib in uveal melanoma

This study examined the use of Darovasertib as a PKC inhibitor prior to and subsequent to enucleation for patients with localised uveal melanoma. The cohorts consisted of a safety cohort of 3 patients (1 month of neoadjuvant treatment followed by up to 6 months of adjuvant treatment), then a treatment cohort of 12 patients (up to 6 months of neoadjuvant treatment, followed by up to 6 months of adjuvant treatment).

• Type: Whole Genome Sequencing
• Archive: European Genome-phenome Archive (EGA)